Yan Xu, Ph.D.
Professor & Dir, Confucius Ins
Director, Confucius Institute
||2121 Euclid Ave. SI 333, Cleveland, OH 44115
|Clinical and Preclinical Pharmacokinetics, Analytical Method Development for Drugs and Metabolites, Lipidomic Profiling and Quantitation of Biomarkers of Human Diseases, Metabolic Flux Analysis of Biochemical Pathways, Metabolomics of Multicomponent Formulations, Mass Spectrometry, Liquid and Gas Chromatography, Enzyme Immunoassay, Capillary Electrophoresis, and Electroanalytical Techniques
Ph.D., University of Cincinnati, 1991
M.S., California State University, Fresno, 1987
B.S., Sun Yat-Sen University, 1982
|Dr. Yan Xu is a Professor of Chemistry. He joined CSU as an Assistant Professor in 1991 and was a Visiting Scientist to the Division of Clinical Sciences at the National Cancer Institute from 2000 to 2001. Dr. Xu was the Director of Graduate Programs and Associate Chair of the Chemistry Department (1999-2000, 2005-2012). He has been the Director of Cancer Pharmacology Core Facility in Case Comprehensive Cancer Center at Case Western Reserve University since 2007 and an Adjunct Staff in the Department of Molecular Cardiology at the Cleveland Clinic Lerner Research Institute since 2000.
Dr. Xu has developed a solid scholarly reputation in the field of bioanalytical chemistry with external funding from NIH, NSF, US-ED, ACS, AACC and NASA, as well as CSU and CWRU, and had over 225 scientific publications and presentations. In addition to his academic responsibility, Dr. Xu has served on the University Judicial Board, University Graduate Petition Committee, University Undergraduate Petition Committee, University Research Council, University Patent Review Committee, University Global Learning Task Force, Presidents Advisory Council on Equal Access & Opportunity, Northeastern Ohio Science and Engineering Fair as Judge, American Chemical Society Cleveland Section as Alternate Councilor and Analytical Topical Group Leader, and he is currently serving on University Faculty Senate, University Graduate Council, University Faculty Affair Committee and COSHP Nominating Committee.
|Honors and Awards:|
|University of Cincinnati Graduate Scholarship, 1987-1991
University of Cincinnati Research Council Summer Fellowship, 1990
Lowenstein-Twitchell-Schubert Fellowship, University of Cincinnati, 1990-1991
American Association for Clinical Chemistry Research Award, Van Slyke Society, 1994
The China-Cornell Fellowship, Rockefeller-Lingnan Foundation, 1996
|The major thrusts of Dr. Xu's research are to develop analytical methods for both quantitative and qualitative determination of therapeutic agents, nucleobases, nucleic acids, lipids, peptides and proteins, and to validate the analytical methods developed for preclinical and clinical evaluation of prognostic, predictive or response molecular markers for cancer treatment, control and prevention.|
|College Chemistry, General Chemistry, Quantitative Analysis, Instrumental Analysis, Chromatography and Separations, Special Topics in Analytical Chemistry, and Pharmacology.|
|American Chemical Society
American Association for Mass Spectrometry
American Association of Pharmaceutical Scientists
American Association of University Professors
|2016- Director, Confucius Institute, CSU
2005- Professor, Department of Chemistry, CSU
2003- Adjunct Faculty, School of Medicine, Case Western Reserve University
2000-2001 Visiting Scientist, Division of Clinical Sciences, National Cancer Institute/National Institutes of Health
2000- Adjunct Staff, Department of Molecular Cardiology, Lerner Research Institute, The Cleveland Clinic
1997-2005 Associate Professor, Department of Chemistry, CSU
1991-1997 Assistant Professor, Department of Chemistry, CSU
|Director of Graduate Programs and Associate Chair, 1999-2000, 2005-2012
Chair, Full Professor Appointment Peer Review Committee, 2011-Present
Chair, Medicinal Chemistry Faculty Search Committee, 2011-2012
Chair, Tenure & Associate Professor Appointment Peer Review Committee, 1997-2001
Tenure & Associate Professor Appointment Peer Review Committee, 1997-Present
Steering Committee of CSU-CCF Joint Ph.D. Program in Chemistry, 1999-2001, 2005
Graduate Committee, 1995-2001, 2005-2015
Undergraduate Committee, 1991-1995, 1997-1999
Workloads & Summer Teaching Assignment Guidelines Committee, 1995-2002, 2005-2009
Department Bylaws Committee, 1996-1999
Chair, Analytical Faculty Search Committee, 1998-1999
Search Committee for Organic Chemistry Term Professor, 1997
Search Committee for Mass Spectrometry Specialist, 1999
Administrative Review Committee, 1998-1999, 2001-2002, 2003-2004
Sheibley Charitable Trust Committee, 2001-2002, 2006-2009, 2012-Present (Chair)
Personnel Affairs Committee, 2001-2002
Appointments and Professional Leave Review, 1991-Present
General Chemistry Committee, 1997-Present
Space, Facilities and Security Committee, 2005-2009
Pharmaceutical Science Faculty Search Committee, 2005-2006
Full Professor Appointment Peer Review Committee, 2005-2009
Graduate Recruitment, Evaluation, Admission and Program Management, 2005-2012
Graduate Student Advising, 1999-2000, 2005-2012
Graduate Program Assessment, 2005-2012
Pharmacology Faculty Search Committee, 2007-2008
Chair, Medicinal Chemistry Faculty Search Committee, 2011-2012
Clinical Chemistry Faculty Search Committee, 2012-2014
Ad Hoc Committee on Renovation of Instrumental Analysis Lab, 2012-Present
University Judicial Board, 1997-1999
University Patent Review Committee, 1998-2000, 2008-2014
University Graduate Faculty Review Committee, 1999-2001
President, Chinese American Faculty & Staff Association, CSU, 1998-1999
University Graduate Petitions Committee, 2002-2004
University Undergraduate Petition Committee, 2002-2004
University Global Learning Task Force, 2003-2004
President's Advisory Council on Equal Access & Opportunity, 2003-2004
College of Science Faculty Affair Committee, 2004-2006
Department of Biological, Geological and Environmental Sciences Full Professor
Appointment Peer Review Committee, 2005-2009
University Research Council, 2005-2007
University Faculty Senate, 2007-2009
College of Science Senate Caucus, 2007-2009
Chair, College of Science Budget and Planning Committee, 2007- 2008
College of Science Steering Committee, 2007-2008
College of Science Associate Dean Search Committee, 2007
College of Science Name the College Committee, April, 2010
COSHP Research Strategic Planning Committee, September 2010-2011.
COSHP Nominating Committee, 2013-2014 (Chair), 2014-Present (Member)
University Graduate Council, 2015-Present
University Faculty Senate, 2015-Present
University Faculty Affairs Committee, 2015-Present
|Judge, Northeastern Ohio Science and Engineering Fair, 1994-1999, 2012
Organizer/Chair, Immunoassays Session, Eastern Analytical Symposium, 1995
Organizer/Chair, Bioanalytical/Clinical Chemistry Session, The 30th Central Regional ACS Meeting, 1997-1998
Contributing Author, Biennial Review of Clinical Chemistry in the Journal Analytical Chemistry, 1993, 1995, 1997, 1999
Analytical Topical Group Leader, ACS, Cleveland Section, 1997
The Edward W. Morley Award Jury, ACS, Cleveland Section, 1997-2000
Co-Chair, Yeager Award Committee, ACS, Cleveland Section, 1997
Alternate Councilor, ACS, Cleveland Section, 2000-2002
Judge, the 2003 Intel International Science & Engineering Fair, Cleveland, OH, USA, May 11-17, 2003.
Grant Reviewer: NSF/CRIF:MU, North Carolina Biotechnology Center, University of Toledo, Appointment & Promotion Reviewer: Case Western Reserve University, 1999
Advisory Committee: Cancer Pharmacology Core Facility, Case Western Reserve University, 2004-2007
NIH/NIEHS, Special Emphasis Panel (NIH ES2012154) for ¿Support of Research Effort to Evaluate Toxicity Following Early Life Exposure to Test Articles for the National Toxicity Program¿, January 17, 2013.
NIH/NIEHS, Special Emphasis Panel (NIH ES2013160) for Support of the Research Effort to Evaluate the Toxic and Carcinogenic Potential of Test Agents in Laboratory Animals for the National Toxicology Program, November 21, 2013.
NIH/NIEHS, Special Emphasis Panel (NIH ES2013180) for Chemistry Services for the National Toxicology Program, February 6, 2014.
Director of Cancer Pharmacology Core, Cancer Comprehensive Cancer Center, CWRU.
Co-Investigator of Clinical Trials at Case Comprehensive Cancer Center. 1) Case 1Y05 - Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors (PI, Jennifer Eads), 2) Case 2Y10 - Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (PI, Paolo Caimi), 3) Case 2411 - Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma (PI, Elma Baron), 4) Case 5913 - Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PI, Basem William)
Faculty Interviewer, CWRU School of Medicine, 2013, 2014.
Manuscript Reviewer: Analytical Biochemistry, The Analyst, Analytical Chemistry, Chromatographia, Clinical Chemistry, Clinica Chimica Acta, Journal of Chromatography, Journal of Pharmaceutical and Biomedical Analysis, and Rapid Communications in Mass Spectromety, Journal of Chromatographic Science
|Organization of Chinese Americans, Greater Cleveland Board of Trustees (1997-1999)|
|P/ACE 2050 Capillary Electrophoresis Control System, Beckman Instruments, $7,280, 1992 (PI).
Development of Analytical Methods for Material Analysis, Lewis Research Center of NASA, $160,365, 1993 (Co-PI, and $173,175, 1994 (Co-PI).
Cystic Fibrosis Gene Mutation Analysis by Capillary Electrophoresis, University Research Council, CSU, $4,094, 1995-97 (PI).
Rapid Electrochemical Enzyme Immunoassay for Small PSA Concentration in Small Volumes, American Association For Clinical Chemistry, $7,500, 1995-97 (PI).
The China-Cornell Research/Teaching Fellowship, Rockefeller Foundation & Lingnan Foundation, $4700, 1996 (PI).
Determination of Lysophosphatic Acid, a Diagnostic Marker for Ovarian and Other Gynecologic Cancers, by Capillary Electrophoresis, University Research Council, CSU, $10,000, 1997-99 (PI).
Chiron ACS-180® Plus Autoanalyzer, Chiron Diagnostics, $33,000, 1997 (PI).
Development of an Analytical Research Center for Biomolecular
Structures, State of Ohio Research Challenge Fund, $150,000, 1997-2000 (Co-PI).
Intergovernmental Personnel Agreement, National Cancer Institute, $61,150,2000-2001 (PI).
Fluorescence Polarization Assay for Quantitative Analysis of TMZ-Induced Abasic Sites in DNA: a Lead to Mechanistic Study of Biochemical Modulation of BER, American Cancer Society, $20,000, 2002-2003 (PI).
Hayes Investment Fund for Mass Spectrometry, State of Ohio Board of Regents, $180,000, 2002-2003 (Co-PI).
Studies of Inhibitors of DNA Repair, National Institute of Health (1 R01 CA86357-5) Research Subcontract through Case Western Reserve University, $21,760, 2003-2004 (PI).
Modulating Base Excision Repair in Tumor Drug Resistance, National Institutes of Health (2 R01 CA86357-5) Research Subcontract through Case Western Reserve University, $284,613, 2004-2009 (PI).
Phase I Study: Methoxyamine and Temozolomide in Patients with Advanced Solid Tumors, National Institutes of Health (1 R21 CA126149-01), $418,208, 2007-2009 (Co-PI).
GAANN Chemistry Scholars, U.S. Department of Education, $383,643, 2007-2010 (PI).
Major Research Instrument Grant, National Science Foundation, $514,962, 2009-2012 (PI).
DNA Metabolizing Enzyme Targeted Therapy/Phase I Trials of Anti-Cancer Agents, NIH/NCI (5U01 CA062502-18), $607,381, 2007-2013 (Dowlati, PI; Xu, Co-PI).
Faculty Research and Development Grant, CSU Office for Research, $20,000, 2012-2013 (Xu, PI).
Undergraduate Research & Creative Achievement Grant, CSU Office of the Vice President for Academic Programs, $13,596, Summer 2012 (Xu, PI).
Targeting Tyrosine Phosphatase SHP2 (PTPN11) for the Treatment of Pediatric Leukemias, National Institutes of Health (R01 HL068212, PI: Qu) Research Subcontract through Case Western Reserve University (RES507809), $35,138, 2012-2013 (PI).
Case Comprehensive Cancer Center Support Grant, NIH/NCI (5P30 CA043703-22), $535,589, 2007-2016 (Gerson, PI; Xu, Director of Cancer Pharmacology Core Facility)